BCAS1 Antikörper (AA 542-584)
Kurzübersicht für BCAS1 Antikörper (AA 542-584) (ABIN1386549)
Target
Alle BCAS1 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
- 
    - 
                                            Bindungsspezifität
- AA 542-584
- 
                                            Homologie
- Human,Mouse,Rat
- 
                                            Aufreinigung
- Purified by Protein A.
- 
                                            Immunogen
- KLH conjugated synthetic peptide derived from human BCAS1
- 
                                            Isotyp
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            Applikationshinweise
- 
                        WB 1:300-5000
 ELISA 1:500-1000
 IHC-P 1:200-400
 IHC-F 1:100-500
 IF(IHC-P) 1:50-200
 IF(IHC-F) 1:50-200
 IF(ICC) 1:50-200
 ICC 1:100-500
- 
                                            Beschränkungen
- Nur für Forschungszwecke einsetzbar
 
- 
                                            
- 
    - 
                                            Format
- Liquid
- 
                                            Konzentration
- 1 μg/μL
- 
                                            Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- 
                                            Konservierungsmittel
- ProClin
- 
                                            Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- 
                                            Lagerung
- 4 °C,-20 °C
- 
                                            Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- 
                                            Haltbarkeit
- 12 months
 
- 
                                            
- 
    - 
                                            : "BCAS1-positive immature oligodendrocytes are affected by the α-synuclein-induced pathology of multiple system atrophy."    in: Acta neuropathologica communications, Vol. 8, Issue 1, pp. 120, (2021)         (PubMed).        
 
 
- 
                                            : "BCAS1-positive immature oligodendrocytes are affected by the α-synuclein-induced pathology of multiple system atrophy."    in: Acta neuropathologica communications, Vol. 8, Issue 1, pp. 120, (2021)         (PubMed).        
- 
    - BCAS1 (Breast Carcinoma Amplified Sequence 1 (BCAS1))
- 
                                            Andere Bezeichnung
- BCAS1/NABC1
- 
                                            Hintergrund
- 
                        Synonyms: AIBC 1, AIBC1, Amplied and overexpressed in breast cancer, BCAS 1, BCAS1, BCAS1_HUMAN, Breast carcinoma amplied sequence 1, Breast carcinoma-amplied sequence 1, Novel amplied in breast cancer 1. Background: NaBC1 is a protein found amplified in most breast carcinoma forms. It is expressed primarily as a cytoplasmic, detergent-stable homodimer that has a tendency to interact with DYNLL1 (PIN) and DYNLL2. Breast tumor lines that exhibit 20q13.2 gene amplification express much higher levels of the protein as compared to the levels found in other breast cancer lines that do not overexpress the NaBC1 mRNA. However, this upregulation does not affect growth rate or anchoring abilities of a cell, indicating the oncogenic properties of NaBC1 differ from that of other oncogenes. 
 Target
- 
                    
 
                                     
                                     
                                    